-
COST-UTILITY ANALYSIS OF RIBOCICLIB PLUS LETROZOLE VERSUS LETROZOLE MONOTHERAPY IN PREMENOPAUSAL AND PERIMENOPAUSAL WOMEN WITH HR+/HER2 ADVANCED BREAST CANCER: A MARKOV MODEL-BASED EVALUATION FROM AN INDIAN HEALTHCARE PERSPECTIVE
Aug 11, 2026, 17:16 PM -
BEYOND THE HEALTHCARE BUDGET: INDIRECT COSTS AS A MAJOR DRIVER OF THE ECONOMIC BURDEN OF CHRONIC DISEASES IN POLAND
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS OF STRATEGIES TO PREVENT RESPIRATORY SYNCYTIAL VIRUS HOSPITALIZATION AMONG INFANTS IN AUSTRIA
Aug 11, 2026, 17:16 PM -
HTA ASSESSMENT OF HIGH-RISK MEDICAL DEVICES IN GERMANY: WHY CLINICAL EVIDENCE FAILS TO PROVE ADDED BENEFIT
Aug 11, 2026, 17:16 PM -
BIOMARKER-DRIVEN TREATMENT PATTERNS AND GUIDELINE CONCORDANCE IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): REAL-WORLD EVIDENCE FROM NORSTELLALINQ CLAIMS AND EHR DATA
Aug 11, 2026, 17:16 PM -
A BUDGET IMPACT ANALYSIS OF REFLUXSTOP FOR THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE IN GERMANY
Aug 11, 2026, 17:16 PM -
IS THE CLINICAL ADDED VALUE A RELEVANT CRITERION FOR ECONOMIC EVALUATION ELIGIBILITY IN FRANCE? INSIGHTS FROM CEESP APPRAISALS (2014-2026)
Aug 11, 2026, 17:16 PM -
STRUCTURAL PATIENT SAFETY FAILURES IN NON-MEDICAL AESTHETIC SETTINGS: EVIDENCE FROM A NATIONWIDE DERMAL FILLER INSPECTION PROGRAM IN SWITZERLAND TO INFORM RISK-BASED REGULATORY POLICY
Aug 11, 2026, 17:16 PM -
ECONOMIC AND SOCIETAL BURDEN OF LUPUS NEPHRITIS IN LATIN AMERICA (LATAM): A MULTICOUNTRY ANALYSIS INCLUDING DIRECT MEDICAL COSTS AND PRODUCTIVITY LOSSES
Aug 11, 2026, 17:16 PM -
THE INCIDENCE, MORTALITY, AND SURVIVAL OF MALIGNANT BILIARY TRACT CANCER IN THE UNITED STATES: A SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) 2000-2023 DATABASE ANALYSIS
Aug 11, 2026, 17:16 PM -
EVALUATING THE FEASIBILITY OF INDIRECT TREATMENT COMPARISONS IN PATIENTS WITH EPNEC TREATED IN SECOND-LINE AND BEYOND (2L+): A GUIDELINE-INFORMED SYSTEMATIC LITERATURE REVIEW AND FEASIBILITY ASSESSMENT
Aug 11, 2026, 17:16 PM -
ECONOMIC AND ORGANIZATIONAL IMPACT OF PRECLINICAL TYPE 1 DIABETES SCREENING IN FRANCE: RESULTS FROM AN ORGANIZATIONAL AND BUDGET IMPACT MODEL
Aug 11, 2026, 17:16 PM -
EX-ANTE HEALTH ECONOMIC EVALUATION OF PERSONALIZED CARE PATHWAYS FOR ICU PATIENTS WITH INFLUENZA-ASSOCIATED PULMONARY ASPERGILLOSIS USING DISCRETE-EVENT SIMULATION
Aug 11, 2026, 17:16 PM -
EXPANDING THE SCOPE: THE SUSTAIN-OBS GOES INTERNATIONAL
Aug 11, 2026, 17:16 PM -
BUDGETIMPACT AND COST CONSEQUENCES OF REZAFUNGIN ADOPTION VERSUS DAILY ECHINOCANDINS FOR INVASIVE CANDIDIASIS IN SAUDI ARABIA
Aug 11, 2026, 17:16 PM -
BEYOND COST-EFFECTIVENESS: ESTIMATING THE SOCIAL VALUE OF PALBOCICLIB OVER ITS LIFECYCLE
Aug 11, 2026, 17:16 PM -
METRELEPTIN EVIDENCE ACROSS CLINICALLY MEANINGFUL HEALTH-STATE TRANSITIONS IN GENERALIZED LIPODYSTROPHY: A MARKOV-BASED MCDA APPROACH
Aug 11, 2026, 17:16 PM -
COMPARISON OF CASE-MIX GROUP AND ICD-10-CA-BASED APPROACHES FOR ADVERSE EVENT COST ESTIMATION IN CANADA
Aug 11, 2026, 17:16 PM -
HOW NEW GLOBAL PRICING & ACCESS POLICIES COULD RESHAPE PRICE EROSION IN EUROPEAN MARKETS
Aug 11, 2026, 17:16 PM -
GUIDANCE ON REAL-WORLD DATA QUALITY FOR MEDICAL DEVICE ARTIFICIAL INTELLIGENCE TO INFORM HTA AND REIMBURSEMENT ACROSS THE EUROPEAN UNION: A SCOPING REVIEW
Aug 11, 2026, 17:16 PM
